BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN

Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company") today reported that its primary treasury asset, the RAIN token, has...

Related news

ENLVEnlivex Therapeutics2026-06-24 13:00 EST

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

CADLCandel Therapeutics2026-08-03 20:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-07-08 20:05 EST

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

XLOXilio Therapeutics2026-07-06 20:30 EST

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLSSELLAS Life Sciences Group, Inc.2026-08-11 20:05 EST

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ELTXElicio Therapeutics, Inc.2026-08-10 12:00 EST

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

RNACCartesian Therapeutics2026-08-07 11:00 EST

Cartesian Therapeutics Announces New Employment Inducement Grants

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States